The EuLITE (Ongoing).

Slides:

Advertisements

Similar presentations

Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.

Advertisements

A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.

Role of Vitamin D in Blood Malignancies Dr Imran Hilal.

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Myeloma and Renal Disease

A feasibility study to explore patient, clinician and GP decision making of acute recurrent tonsillitis for NATTINA: The NAtional Trial of Tonsillectomy.

Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Depression: Improving Recruitment into Clinical Trials David A Richards, Professor of Mental Health Services Research.

AL Amyloidosis and renal complications Alex Legg PhD Scientific Affairs Manager The Binding Site Distributor in Poland BIOKOM.

Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo- controlled, randomised.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Corre J et al. Proc ASH 2014;Abstract 180.

Protein casts, nodular glomerulosclerosis in a graft biopsy samples Agnieszka Perkowska-Ptasinska Transplantation Institute, Medical University of Warsaw,

Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

 Exemplary Care  Cutting-edge Research  World-class Education  Raghavan Murugan MD, MS, FRCP Associate Professor Dept. of Critical Care Medicine Clinical.

Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.

Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney Sophina Hissaund FY2.

Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.

High Cut-Off Hemodialyzers Efficiently Remove Immunoglobulin Free Light Chains And Reduce Tubular Injury Induced By Plasma Of Patients With Multiple Myeloma.

Acute kidney injury in cancer patients Wim Van Biesen for Norbert Lameire Em prof of Medicine University Hospital Gent, Belgium Tbilisi, october 2015.

Myeloma and the Kidney Ryan Sanford How Often is the Kidney Involved Symptomatic MM: CRAB – hyperCalcemia – Renal dysfunction – Anemia – Bone.

The Evaluate Trial. Rationale and Design of the Eplerenone Combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment.

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

The balANZ Trial. Source Johnson DW, Clarke M, Wilson V, et al. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral.

The DVD Trial. Source Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or.

The RAVE Study Renal Athersosclerotic Revascularization Evaluation Reference Tobe SW, Atri M, Perkins N, et al. Renal Athersosclerotic revascularization.

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.

The STAR Study. Cardiovascular Disease Antihypertensives The STAR Study Stent Placement in Patients with Atherosclerotic Renal Artery Stenosis and Impaired.

Poster Title Dr. Stasinopoulos Dimitrios, Assistant Professor Physiotherapy Physiotherapy Program, Department of Health Sciences School of Sciences European.

The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.

Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.

Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.

Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

The ALERT Trial.

The ADEMEX Trial Adequacy of PD in Mexico Reference

IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.

The EuLITE (Ongoing) Source

An elderly suffering from acute renal failure

Intensive Hemodialysis: Applied Clinical Practice

ASCT for AL Seok Jin Kim

Verstovsek S et al. Proc ASH 2011;Abstract 793.

Goede V et al. Proc ASH 2014;Abstract 3327.

C. Chalklin, C. Colmont, A. Zaidi, J. Warden-Smith, E. Ablorsu

The CANUSA Trial Reference

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Enlightening light chain deposition disease

Nat. Rev. Cardiol. doi: /nrcardio

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Vesole DH et al. Proc ASH 2010;Abstract 308.

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Figure 2 Milestones in paediatric acute kidney injury (AKI) research

Nat. Rev. Cardiol. doi: /nrcardio

End point Fenoldopam, n (%) Dopamine, n (%) p

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Volume 73, Issue 11, Pages (June 2008)

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

European Office Goswell House 134 Peascod Street Windsor, UK

Hepatology may have problems with putative surrogate outcome measures

Branford S et al. Proc ASH 2013;Abstract 254.

Forest plots for randomised and cluster randomised controlled trials from Cochrane review Biomarkers as point-of-care tests to guide prescription of antibiotics.

Volume 60, Issue 3, Pages (September 2001)

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Ionized-to-total magnesium (Mg) and calcium (Ca) ratios are lower in patients on hemodialysis than those in patients not on dialysis. Ionized-to-total.

Dialysis limitations. Dialysis limitations. (A) Recent data from observational studies and randomized, clinical trials indicate significant limitations.

Presentation transcript:

The EuLITE (Ongoing)

The EuLITE (Ongoing) Source Hutchison CA, Cook M, Heyne N, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials. 2008;9:55.

Background Nearly half of multiple myeloma patients have renal impairment at presentation. The principal cause of this severe renal failure is cast nephropathy, a direct consequence of high concentrations of monoclonal free light chains (FLCs) in patients’ sera. Hence, a treatment option for these patients is direct removal of monoclonal FLCs from the serum by extended hemodialysis. Results of early pilot studies suggest that this procedure is not only effective at removing FLCs, but it is also associated with improved clinical outcome.

Aim To evaluate, in a controlled setting, the clinical benefits of FLC removal hemodialysis in patients with cast nephropathy, dialysis-dependent acute renal failure and de novo multiple myeloma.

Methods

Conclusion This trial will investigate the potential role of FLC removal hemodialysis in the management of patients with new multiple myeloma, cast nephropathy and dialysis-dependent renal failure. If efficacious, FLC removal hemodialysis will offer clinicians new options in the management of these patients with historically very poor outcome.